AI-generated summary
The authors pooled 12 randomized controlled trials covering 574 participants to assess photobiomodulation for primary burning mouth syndrome. They report that it was associated with less pain and better quality of life compared with placebo, with no treatment-related adverse events reported. The authors state that more evidence is still needed to confirm efficacy and safety.
- Participants
- 574
- Studies included
- 12
- Who or what was studied
- Patients with primary burning mouth syndrome (pBMS)
- Limits stated in the abstract
- The authors state that more evidence is still required to warrant efficacy and safety, and the abstract does not report wavelengths or dosing parameters.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on doi.org.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Meta-analysis, Systematic review, Adverse event. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.